DESONATE Drug Patent Profile

Which patents cover Desonate, and when can generic versions of Desonate launch?

Desonate is a drug marketed by Leo Pharma As and is included in one NDA.

The generic ingredient in DESONATE is desonide. There are thirty-one drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the desonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Desonate

A generic version of DESONATE was approved as desonide by SUN PHARMA CANADA on August 3^rd, 1994.

Summary for DESONATE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DESONATE

Paragraph IV (Patent) Challenges for DESONATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DESONATE	Gel	desonide	0.05%	021844	1	2010-12-01

US Patents and Regulatory Information for DESONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	DESONATE	desonide	GEL;TOPICAL	021844-001	Oct 20, 2006		DISCN	Yes	No

International Patents for DESONATE

See the table below for patents covering DESONATE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	030093	SISTEMA PARA LA DISTRIBUCION TOPICA DEL GEL
Austria	429922
Australia	2001279002
Australia	7900201
Brazil	0113247
Canada	2417646	SYSTEME DE DISTRIBUTION D'UN GEL TOPIQUE (TOPICAL GEL DELIVERY SYSTEM)

Supplementary Protection Certificates for DESONATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	C300617	Netherlands		PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992	2013C/060	Belgium		PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506
2435024	LUC00208	Luxembourg		PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
1304992	2013/044	Ireland		PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
2435024	SPC/GB21/029	United Kingdom		PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210
1304992	132013902214376	Italy		PRODUCT NAME: CLINDAMICINA FOSFATO E TRETINOINA(ACNATAC); AUTHORISATION NUMBER(S) AND DATE(S): PA1332/043/001, 20130322;042056010/M - 022/M, 20130718

Investment Scenario, Market Dynamics, and Financial Trajectory for DESONATE

Last updated: February 3, 2026

Executive Summary

DESONATE (generic name: Desonide) is a topical corticosteroid used primarily for treating inflammatory and pruritic skin conditions such as eczema, psoriasis, and dermatitis. While existing as a well-established treatment, recent market developments and pipeline innovations influence its investment viability. This analysis evaluates the current market landscape of DESONATE, explores the potential for growth, assesses competitive and regulatory factors, and projects financial trajectories for stakeholders.

Overview of DESONATE

Aspect	Detail
Active Ingredient	Desonide
Drug Class	Topical corticosteroid
Approved Indications	Eczema, psoriasis, dermatitis
Market Entry Year	1980s (initial approval), with generics since early 2000s
Patent Status	Patent expiration (approx. 2010s)
Formulations	Cream, ointment, foam

Source: [1], [2]

Market Landscape and Dynamics

Global Market Size and Growth Rate

Region	2022 Revenue (USD millions)	CAGR (2021-2026)	Key Drivers
North America	450	4.2%	High prevalence of skin conditions, strong OTC market
Europe	300	3.8%	Regulated healthcare systems, aging populations
Asia-Pacific	250	7.1%	Rising disposable income, urbanization, increased awareness

Total Global Market (2022): ~$1 billion

Projection (2026): ~$1.35 billion

Sources: [3], [4]

Market Segmentation

Segment	Share (%)	Comments
Prescription topical corticosteroids	65%	Dominates due to established efficacy
Over-the-counter products	35%	Growing influence, especially in North America

Market Share Shifts: Increased OTC access may influence prescription volume trends.

Competitive Landscape

Competitor	Products	Market Share (%)	Notable Features
Brand-name (e.g., Elocon)	Mometasone furoate	40%	Higher potency formulations, brand loyalty
Generics (Desonide-based)	Desonate, others	50%	Price competitiveness, wider formulary inclusion
Emerging alternatives	Calcineurin inhibitors, biologics	10%	For severe or resistant cases

Market Drivers and Barriers

Drivers	Barriers
Rising prevalence of chronic skin diseases	Patent cliffs for older formulations
Increased healthcare access in emerging markets	Competition from new biologic therapies
Clinician and patient preference for topical agents	Regulatory hurdles for new formulations

Regulatory Context: US FDA, EMA, and other authorities standardize safety and efficacy requirements, impacting market entry.

Financial Trajectory and Investment Opportunities

Revenue Forecasting

Year	Estimated Global Revenue (USD millions)	Assumptions
2023	1,020	Slight growth driven by increased OTC sales in emerging markets
2024	1,060	Expansion in Asia-Pacific, new formulation launches
2025	1,110	Market penetration increases, improved formulary coverage
2026	1,350	Mature growth, potential generic crush, new indications

Compound Annual Growth Rate (2022-2026): approximately 7.9%

Profitability and Cost Structure

Cost Element	Approximate % of Revenue	Details
R&D	5-8%	For formulation improvements or new indications
Manufacturing	15-20%	Fixed costs, scale efficiencies
Regulatory and Compliance	3-5%	NDA submissions, safety monitoring
Marketing and Distribution	10-15%	Brand positioning, provider education
Gross Margin	60-70%	Favorable due to generic market dynamics

Risks and Mitigation

Risk	Impact	Mitigation Strategies
Regulatory delays	Revenue shortfalls	Engage early with regulators, robust clinical data
Patent litigation	Market access delays	Patent landscape analysis, strategic patent filings
New competitors	Market share erosion	Price strategies, formulary negotiations
Market saturation	Profit margin compression	Diversify indications, geographic expansion

Strategic Investment Insights

• Short- to medium-term focus on emerging markets with high growth potential (e.g., India, Southeast Asia).
• Potential for formulation innovation (e.g., higher penetration, combination products).
• Monitoring patent status and regulatory corridors for generic entry points.

Comparison with Other Topical Corticosteroids

Drug Name	Potency	Approved Indications	Patent Status	Market Share (%)	Notable Advantages
Mometasone (Elocon)	Moderate	Same as Desonide	Patent expired	40	Higher potency, established brand loyalty
Hydrocortisone	Low	Mild dermatitis	Patent expired	15	Widely available, OTC
Betamethasone dipropionate	High	Severe dermatitis, psoriasis	Patent expired	25	Potent, rapid action

Note: Desonide holds a niche for mild to moderate conditions with favorable safety profile.

Regulatory and Policy Environment

Market	Regulatory Agency	Recent Policies	Impact on DESONATE
United States	FDA	Encouragement of generic drug substitution	Facilitates market entry, price competition
European Union	EMA	Strict safety and efficacy standards	Delays for new formulations, supports generics
China and India	NMPA, CDSCO	Fast-track approvals for generics in traditional markets	Accelerates growth in emerging markets

Emerging Policy Trends: Accelerated approval pathways, incentivization of biosimilars, and increased scrutiny of off-label use.

Conclusion: Investment Outlook and Strategic Recommendations

• Market Opportunity: The global demand for topical corticosteroids, including DESONATE, is projected to grow steadily, driven by rising skin disease prevalence and expanding healthcare access in emerging markets.
• Competitive Position: Generic DESONATE benefits from cost advantages, but must innovate or diversify to maintain market share amid patent expirations and competition.
• Regulatory Outlook: Stable with predictable pathways; however, adhering to evolving safety standards remains crucial.
• Financial Trajectory: Expected to grow at an approximate CAGR of 7.9%, with potential accelerations from market expansion and formulations.
• Investment Risks: Market saturation, competition, regulatory delays, and pricing pressures. Mitigation involves geographic diversification and pipeline innovation.

Key Takeaways

• Market Growth: Steady global expansion emphasizes DESONATE's sustained relevance.
• Pricing Competitiveness: Generics dominate due to price sensitivity; differentiation strategies are limited.
• Pipeline Development: Opportunities in novel formulations or combination products could enhance value.
• Emerging Markets: Exhibit high growth potential; tailored strategies needed.
• Regulatory Dynamics: Favorable for generics but require vigilant compliance.

FAQs

1. What are the main drivers of DESONATE's market growth?
   Increasing prevalence of skin conditions, expanded OTC availability, and growth in emerging markets.

2. How does patent expiration impact DESONATE's market share?
   Patent expiry has led to increased generic competition, reducing prices and profit margins but expanding accessibility.

3. Are there any new formulations or indications in the pipeline for DESONATE?
   Currently, no major pipeline developments are publicly known; focus remains on formulations like foam and combination creams.

4. What regulatory hurdles exist for expanding DESONATE's indications?
   Additional clinical trials and safety evaluations are necessary, which can delay approval and increase costs.

5. How does DESONATE compare to other topical corticosteroids in terms of safety?
   Desonide has a favorable safety profile, especially for long-term use, compared to higher potency corticosteroids.

References

[1] U.S. Food and Drug Administration (FDA). Desonide Product Label. 2022.

[2] European Medicines Agency (EMA). Summary of Product Characteristics for Desonide. 2021.

[3] MarketsandMarkets. Topical Corticosteroids Market Analysis Report. 2022.

[4] Grand View Research. Global Dermatology Drugs Market. 2023.